Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora SpineASAPF -11.41%39 Revenue per Share is $0.24 as of Mar. 2026. GuruFocus rates ASAPF with a GF Score™ of 39/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 754 Medical Devices & Instruments companies, Aurora Spine ranks worse than 54.38% on this metric.
Aurora Spine's revenue per share for the
three
months ended in Mar. 2026 was $0.06.
Aurora Spine's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.24.
Warning Sign:
Aurora Spine Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Aurora Spine was 0.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 2.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 9.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Aurora Spine's Revenue per Share or its related term are showing as below:
ASAPF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6 Med: 2.4 Max: 16.3
Current: 2.4
During the past 13 years, Aurora Spine's highest 3-Year average Revenue Per Share Growth Rate was 16.30% per year. The lowest was -6.00% per year. And the median was 2.40% per year.
ASAPF's 3-Year Revenue Growth Rate is ranked worse than 54.38% of 754
companies
in the Medical Devices & Instruments industry
Industry Median: 3.8
vs ASAPF: 2.40
Aurora Spine (OTCPK:ASAPF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Aurora Spine Revenue per Share Related Terms
Aurora Spine Revenue per Share Historical Data
* Premium members only.
The historical data trend for Aurora Spine's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASAPF vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, Aurora Spine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aurora Spine's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Aurora Spine's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Spine (ASAPF) has a Revenue per Share of $0.24 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Aurora Spine and its competitors. According to the industry distribution chart, Aurora Spine ranks #410 out of 754 companies in the Medical Devices & Instruments industry, placing it in the top 54.4%.
Is Aurora Spine's Revenue per Share too high?
Aurora Spine's current Revenue per Share is $0.24. The Medical Devices & Instruments industry median Revenue per Share is 3.80. Aurora Spine's value of $0.24 is 93.7% below this industry median. Based on the distribution chart, Aurora Spine ranks #410 out of 754 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aurora Spine has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #410 out of 754 companies for Revenue per Share. This places Aurora Spine in the lower half of its industry. The industry median Revenue per Share is 3.80. Aurora Spine's value of $0.24 is 93.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.80, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current Revenue per Share of $0.24 is 93.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Aurora Spine and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current Revenue per Share is $0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.14 — trading 44.8% below its estimated fair value. The current Revenue per Share is $0.24 and 93.7% below the Medical Devices & Instruments industry median of 3.80. Aurora Spine's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current Revenue per Share is $0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.14 is trading 44.8% below its estimated GF Value™ of $0.26.
GuruFocus considers Aurora Spine to be Possible Value Trap.
Key valuation signals for ASAPF:
Revenue per Share: $0.24
GF Value™: $0.26 vs. price of $0.14 (44.8% below fair value)
Industry Position: 93.7% below the Medical Devices & Instruments median (#410 of 754)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
39GF Score
Get the complete analysis for ASAPF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
